不含防腐剂的透明质酸钠 0.1%滴眼剂治疗地夸磷索 3%滴眼剂治疗干眼综合征的增效作用。
Additive Effect of preservative-free sodium hyaluronate 0.1% in treatment of dry eye syndrome with diquafosol 3% eye drops.
机构信息
*Department of Ophthalmology, Chuncheon Sacred Heart Hospital, College of Medicine, Hallym University, Gangwon-Do, Korea; †Department of Ophthalmology and Visual Science, College of Medicine, The Catholic University of Korea, Seoul, Korea; and ‡Institute of Clinical Medicine Research, Bucheon St. Mary's Hospital, Bucheon, Gyunggi-Do, Korea.
出版信息
Cornea. 2014 Sep;33(9):935-41. doi: 10.1097/ICO.0000000000000213.
PURPOSE
The aim of this study was to evaluate the treatment effect of diquafosol 3% with preservative-free sodium hyaluronate 0.1% eye drops in dry eye syndrome.
METHODS
In total, 150 patients with dry eye syndrome were divided randomly into 3 groups. Group 1 (50 patients) was treated 4 times daily with preserved sodium hyaluronate 0.1%, group 2 (50 patients) was treated 4 times daily with diquafosol 3%, and group 3 (50 patients) was treated 4 times daily with diquafosol 3% and preservative-free sodium hyaluronate 0.1% eye drops for 3 months. Ocular surface disease index (OSDI) score, tear film break-up time, Schirmer I test, corneal fluorescein staining, and impression cytology were evaluated.
RESULTS
There were significant improvements in the OSDI score, tear film break-up time, Schirmer I score, fluorescein and Rose Bengal staining, goblet cell density, and impression cytological findings in groups 2 and 3 compared with those for group 1 in patients with dry eye syndrome at 1, 2, and 3 months (P < 0.05). There were statistically significant improvements in the OSDI score (-8.48 ± 0.97, -5.69 ± 0.78; P = 0.02), fluorescein (-1.43 ± 0.21, -1.02 ± 0.18; P = 0.03), and Rose Bengal staining (-1.12 ± 0.26, -0.75 ± 0.12; P = 0.03), goblet cell density (89.65 ± 14.39, 70.36 ± 16.75; P = 0.03), and impression cytological findings (-0.53 ± 0.12, -0.34 ± 0.90; P = 0.01) in group 3 compared with those in group 2 at 3 months.
CONCLUSIONS
Treatment with diquafosol 3% with preservative-free sodium hyaluronate 0.1% was more effective than diquafosol 3% monotherapy or treatment with preserved sodium hyaluronate 0.1% in dry eye syndrome. Preservative-free sodium hyaluronate 0.1% eye drops can increase the effect of diquafosol 3% in dry eye syndrome.
目的
本研究旨在评估不含防腐剂的透明质酸钠 0.1%滴眼液与地夸磷索 3%联合治疗干眼症的疗效。
方法
将 150 例干眼症患者随机分为 3 组。第 1 组（50 例）给予含防腐剂的透明质酸钠 0.1%，每日 4 次；第 2 组（50 例）给予地夸磷索 3%，每日 4 次；第 3 组（50 例）给予地夸磷索 3%联合不含防腐剂的透明质酸钠 0.1%，每日 4 次，共治疗 3 个月。评估眼表疾病指数（OSDI）评分、泪膜破裂时间（BUT）、泪液分泌试验（Schirmer I 试验）、角膜荧光素染色、结膜印迹细胞学检查。
结果
治疗 1、2、3 个月后，与第 1 组相比，第 2 组和第 3 组的 OSDI 评分、BUT、Schirmer I 试验、角膜荧光素和孟加拉红染色、杯状细胞密度及结膜印迹细胞学检查均有明显改善（P<0.05）。第 3 组 OSDI 评分改善程度优于第 2 组（-8.48±0.97 比-5.69±0.78；P=0.02），角膜荧光素染色改善程度优于第 2 组（-1.43±0.21 比-1.02±0.18；P=0.03），孟加拉红染色改善程度优于第 2 组（-1.12±0.26 比-0.75±0.12；P=0.03），杯状细胞密度改善程度优于第 2 组（89.65±14.39 比 70.36±16.75；P=0.03），结膜印迹细胞学检查改善程度优于第 2 组（-0.53±0.12 比-0.34±0.90；P=0.01）。
结论
地夸磷索 3%联合不含防腐剂的透明质酸钠 0.1%治疗干眼症的效果优于地夸磷索 3%单药治疗或含防腐剂的透明质酸钠 0.1%治疗。不含防腐剂的透明质酸钠 0.1%滴眼液可增强地夸磷索 3%治疗干眼症的效果。
Zotero 插件